Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China’s National Reimbursement Drug List
–the only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinoma SHANGHAI, China, Dec. 03, 2021 (GLOBE NEWSWIRE)